Drug Profile
NA 808
Alternative Names: NA808Latest Information Update: 29 Aug 2012
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors; Serine palmitoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 29 Aug 2012 Discontinued - Phase-I for Hepatitis C in Japan (Parenteral) before 2012
- 29 Aug 2012 Discontinued - Phase-I for Hepatitis C in USA (Parenteral) before 2012
- 10 Feb 2011 Suspended - Phase-I for Hepatitis C in Japan (Parenteral)